Key result
Doxazosin increased HDL-C and decreased triglycerides and VLDL-T compared to atenolol in patients with mild to moderate hypertension.
Why the study?
Does doxazosin improve fasting blood lipids compared to atenolol in patients with mild to moderate hypertension?
RCT (n=131)
Double-blind
randomized
Does doxazosin improve fasting blood lipids compared to atenolol in patients with mild to moderate hypertension?
In patients with mild to moderate hypertension, doxazosin produces favorable changes in lipid profiles compared to atenolol.
Answers are grounded in this paper and cite their sources.
Doxazosin may be favored over atenolol when lipids matter in hypertension; confirms alpha- versus beta-blocker metabolic differences in RCT.
A randomized double-blind trial comparing the alpha-adrenergic blocker doxazosin and the beta-adrenergic blocker atenolol was completed by 131 patients with mild to moderate hypertension. Blood pressure and fasting blood lipids were determined at baseline and 4, 12, and 24 weeks of treatment. At entry, plasma lipids and lipoproteins were similar in those patients randomized to doxazosin or atenolol. After 24 weeks of treatment with atenolol, there were significant (P < .05) decreases in high-density lipoprotein cholesterol (HDL-C) and increases in triglycerides and very-low-density triglycerides (VLDL-T). In contrast, doxazosin was associated with significant (P < .05) increases in HDL-C and decreases in triglycerides and VLDL-T. There were no significant differences in HDL apolipoprotein (apo) A-I or low-density lipoprotein apoB between the drugs, but atenolol decreased the ratio of HDL-C to apoA-I, and doxazosin increased this ratio, differences that were statistically significant (P < .002). Neither apoA-I nor apoB concentration at baseline nor apoE phenotype was predictive of the lipid responses during antihypertensive treatment with either drug. Thus, there are significant favorable changes in HDL-C, total triglycerides, and VLDL-T between patients with mild to moderate hypertension and normal plasma lipids when treated with the alpha-blocker doxazosin compared with the beta-blocker atenolol. Plasma lipid or apo concentrations were not predictive of their lipid response during antihypertensive therapy with either of these agents.
No takes yet. Share an insight, caveat, or question.
Rabkin et al. (1994) conducted an RCT in mild to moderate hypertension (n=131). Doxazosin vs. Atenolol was evaluated on Changes in HDL-C, triglycerides, and VLDL-T (p=<.05). Doxazosin increased HDL-C and decreased triglycerides and VLDL-T compared to atenolol in patients with mild to moderate hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: